TP53 and lung carcinoma: Furthermore, in KRAS/p53 mutant lung tumors, the effect of anti-PD-1 therapy was more pronounced in IL-17C-deficient KRAS lung cancer mice than in wild-type mice, suggesting that blocking IL-17C may improve the response to anti-PD-L1 therapy in lung cancer patients (223).